The results of studies directly show that two-year maintenance treatment with rituximab at 2 months, PFS was significantly prolonged, delaying the need to deploy additional therapy and improves the quality of treatment response in patients with FL who responded to first treatment line chemotherapy in combination with rituximab. The administration of rituximab was well tolerated and does not adversely affect the quality of life for patients.